These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 26795844

  • 1. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E.
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M.
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [Abstract] [Full Text] [Related]

  • 4. A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
    Jain S, Kapoor G, Koneru S, Vishwakarma G.
    Support Care Cancer; 2018 Sep; 26(9):3091-3097. PubMed ID: 29564625
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.
    Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
    Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID.
    Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
    [Abstract] [Full Text] [Related]

  • 13. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A.
    Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J.
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [Abstract] [Full Text] [Related]

  • 15. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M.
    Ann Oncol; 2018 Feb 01; 29(2):452-458. PubMed ID: 29092012
    [Abstract] [Full Text] [Related]

  • 16. Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
    Kovács G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E.
    Future Oncol; 2017 Aug 01; 13(19):1685-1698. PubMed ID: 28569078
    [Abstract] [Full Text] [Related]

  • 17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr 01; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
    Tian W, Wang Z, Zhou J, Zhang S, Wang J, Chen Q, Huang C, Pan L, Zhang L, Huang J, Shen H, Lin T.
    Med Oncol; 2011 Mar 01; 28(1):71-8. PubMed ID: 20049561
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM.
    Lancet Oncol; 2015 Sep 01; 16(9):1079-1089. PubMed ID: 26272769
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
    Nakagaki M, Barras M, Curley C, Butler JP, Kennedy GA.
    Support Care Cancer; 2017 Feb 01; 25(2):607-613. PubMed ID: 27738796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.